Anti-Transcriptional Intermediary Factor 1 Gamma Antibody-Positive Dermatomyositis Concomitant with Diffuse Large B-Cell Lymphoma: Case Report and Literature Review
Case Reports in Oncology · 2026-08-27 · 19 (1) · 1451-1458
DOI: 10.1159/cro/abzag037 ↗Abstract
Introduction: Anti-transcriptional intermediary factor 1 gamma antibody-positive dermatomyositis (anti-TIF1-γ-DM) is a paraneoplastic syndrome occurring in various neoplasms, but reports elaborating on anti-TIF1-γ-DM patients accompanied by lymphoma are scarce. We report 2 patients with diffuse large B-cell lymphoma (DLBCL) complicated by anti-TIF1-γ-DM and carried out TIF1-γ immunohistochemistry on tissue sections of DLBCL and skin of anti-TIF1-γ-DM patients and controls. Genetic analysis of exons 2 and 10 of TRIM33, the gene coding TIF1-γ, was also carried out in DLBCL and skin samples of anti-TIF1-γ-DM patients and controls to look for recurrent mutations. Case Presentation: Case 1 was a 65-year-old male and case 2 was a 52-year-old male, and both patients presented with DLBCL complicated by anti-TIF1-γ-DM. R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone) therapy led to remissions of both anti-TIF1-γ-DM and DLBCL in both cases. Immunohistochemistry showed strong TIF1-γ expression in DLBCL and skin samples from both patients with anti-TIF1-γ-DM and controls. Mutations in exons 2 and 10 of TRIM33 have been previously reported in DLBCL cells of an anti-TIF1-γ-DM patient, but analysis of the same exons revealed no recurrent mutations in our cases. Conclusion: Anti-TIF1-γ-DM very often presents with a concomitant neoplasm, and a systemic evaluation for malignancy including lymphoma is mandatory. The etiology of anti-TIF1-γ-DM in patients with lymphoma remains unknown, and the underlying mechanisms have yet to be elucidated.
EUVIMED